CTOR
Citius Oncology, Inc.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.86
+8.56%Margins
Gross margin
53.1%
EBITDA margin
-607.0%
EBIT margin
-665.6%
Net margin
-648.3%
FCF margin
-277.3%
-114.1%
Return on equity
-41.1%
Return on assets
-93.5%
Return on invested capital
0.07x
Asset turnover
-$19.7M
Cash from operations
$0.18
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026